Discover the latest guidelines on appropriate diagnosis, evaluation, and risk stratification of non-muscle invasive bladder cancer (NMIBC) in this engaging and expert-led live webinar. Learn about advances in the treatment landscape and emerging clinical data for novel chemo ablative therapies in low-grade, intermediate-risk (LG-IR) NMIBC. Hear expert insights on considerations for integration of novel chemo ablative therapies into clinical practice, including patient eligibility, treatment selection, and adverse event management. Don’t miss the chance to have your questions answered in the live Q & A with the experts!
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/virtual/ask-experts-latest-advances-treatment-low-grade-intermediate-risk-non-muscle
- Start Date: 2024-12-17 06:00:00
- End Date: 2024-12-17 06:00:00
- Credit Details: AAPA Category 1 Credit™️: 0.75 hours
AMA PRA Category 1 Credit™️: 0.75 hours
Nursing: 0.75 hours
Pharmacy: 0.75 hours - Commercial Support: Source: Urogen Pharma, Inc. - Amount: 46666.67 - Is Kind Support: False
- Activity Type: Live Course
- CME Finder Type: Conference
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest